Arkolith/Insider Trading/ORIC/Form 4

Heyman Richard A.

DirectorOric Pharmaceuticals, Inc. (ORIC) · full profile →Form 4 · filed Oct 3, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 3, 2025Option exercise(M)31K$1.60$50K44K
Oct 3, 2025Option exercise(M)1K$3.75$5K45K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 3, 2025Option exercise(M)1K—$052K
Oct 3, 2025Option exercise(M)13K—$034K
Oct 3, 2025Option exercise(M)18K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001584759-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML